Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats

Neurochemical Research

Volumn 32, Issue 6, 2007, Pages 965-972

  Budni, Patrícia ^a   De Lima, Maria Noemia Martins ^b   Polydoro, Manuela ^c   Moreira, José Cláudio Fonseca ^c   Schroder, Nadja ^b   Dal Pizzol, Felipe ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Hippocampus; Iron; Neuroprotection; Oxidative stress; Selegiline; Substantia nigra

Indexed keywords

IRON; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; HIPPOCAMPUS; MALE; NEUROPROTECTION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; ANTIPARKINSON AGENTS; BRAIN CHEMISTRY; FEMALE; HIPPOCAMPUS; IRON; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PREGNANCY; RATS; RATS, WISTAR; SELEGILINE; SUBSTANTIA NIGRA; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

RATTUS;

EID: 34248159387     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-006-9249-x     Document Type: Article

References (62)

1. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23(5):795-807
2. Halliwell B, Gutteridge JMC (1999) Free radicals in biology and medicine. Oxford University Press, Oxford
3. Halliwell B, Gutteridge JMC (1990) Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 186:1-85
4. Petrat F, de Groot H, Sustmann R et al (2002) The chelatable iron pool in living cells: a methodically defined quantity. Biol Chem 383:489-502
5. Ryan TP, Aust SD (1992) The role of iron in oxygenmediated toxicities. Crit Rev Toxicol 22:119-141
6. Stohs SJ, Bagchi D (1995) Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 18:321-336
7. Milman N, Pedersen P, Steig T et al (2001) Clinically overt hereditary hemochromatosis in Denmark 1948/1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 80:737-744
8. Rasmussen M, Folsom AR, Catellier DJ et al (2001) A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 154:739-746
9. Rauen U, Petrat F, Sustmann R et al (2004) Iron-induced mitochondrial permeability transition in cultured hepatocytes. J Hepatol 40(4):607-615
10. Yang Q, McDonnell SM, Khoury MJ et al (1998) Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 129: 946-953
11. Beckman LE, Van Landeghem GF, Sikstrom C et al (1999) Interaction between hemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 20:1231-1233
12. Li J, Zhu Y, Singal DP (2000) HFE gene mutations in patients with rheumatoid arthritis. J Rheumatol 27:2074-2077
13. Walker EMJ, Walker SM (2000) Effects of iron overload on the immune system. Ann Clin Lab Sci 30:354-365
14. Berg D, Gerlach M, Youdim MBH et al (2001) Brain iron pathways and their relevance to Parkinsońs disease. J Neurochem 79:225-236
15. Sayre LM, Perry G, Atwood CS (2000) The role of metals in neurodegenerative diseases. Cell Mol Biol 46:731-741
16. Floyd RA, Carney JM (1992). Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 32(Suppl):S22-S27
17. Hill JM, Switzer RC (1984) The regional distribution and cellular localization of iron in the rat brain. Neuroscience 11(3):595-603
18. Kim NH, Park SJ, Jin JK et al (2000) Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice. Brain Res 884(1-2):98-103
19. Dexter DT, Carayon A, Javoy-Agid F et al (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953-1975
20. Dexter DT, Wells FR, Lees AJ et al (1994) Increased nigral iron content and alteration in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836
21. Jellinger KA (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14(2):115-140
22. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl 126:23-33
23. Lee DW, Sohn HO, Lim HB et al (1999) Alteration of free radical metabolism in the brain of mice infected with scrapie agent. Free Radic Res 30(6):499-507
24. Liu R, Liu IY, Bi X et al (2003) Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics Proc. Natl Acad Sci USA 100(14):8526-8531
25. Fernandez-Espejo E (2004) Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 29(1):15-30
26. Kiray M, Bagriyanik HA, Pekcetin C et al (2006) Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol Res 55(2):205-212
27. Magyar K, Szende B (2004) (-)-Deprenyl, a selective MAOB inhibitor, with apoptotic and anti-apoptotic properties. Neurotox 25(1-2):233-242
28. Magyar K, Szende B, Lengyel J et al (1996) The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. J Neural Transm Suppl 48:29-43
29. Olanow CW (1996) Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J Neural Transm Suppl 48:75-84
30. Heinonen EH, Lammintausta R.A (1991) Review of the pharmacology of selegiline. Acta Neurol Scand Suppl 136:44-59
31. De Lima MN, Polydoro M, Laranja DC et al (2005) Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur J Neurosci 21(9):2521-2528
32. Schröder N, Fredriksson A, Vianna MRM et al (2001) Memory deficits in adult rats following postnatal iron administration. Behav Brain Res 124:77-85
33. Brandeis R, Sapir M, Kapon Y et al (1991) Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. Pharmacol Biochem Behav 39(2):297-304
34. De Lima MN, Laranja DC, Caldana F et al (2005) Selegiline protects against recognition memory impairment induced by neonatal iron treatment. Exp Neurol 196(1):177-183
35. Head E, Hartley J, Kameka AM et al (1996) The effects of l-deprenyl on spatial short term memory in young and aged dogs. Prog Neuropsychopharmacol Biol Psychiatry 20:515-530
36. Kiray M, Uysal N, Sonmez A et al (2004) Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains. Neurosci Lett 354(3):225-228
37. Kiray M, Bagriyanik HA, Pekcetin C et al (2006) Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol Res 55(2):205-212
38. Maia FD, Pitombeira BS, Araujo DT et al (2004) l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats. Cell Mol Neurobiol 24:87-100
39. Stoll S, Hafner U, Pohl O et al (1994) Age-related memory decline and longevity under treatment with selegiline. Life Sci 55:2155-2163
40. Yavich L, Sirvio J, Heinonen E et al (1993) The interaction of L-deprenyl and scopolamine on spatial learning/memory in rats. J Neural Transm Park Dis Dement Sect 6(3):189-97
41. Esterbauer H, Cheeseman KH et al (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Meth Enzymol 186:407-421
42. Lowry OH, Rosebrough NJ, Farr AL et al (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275
43. Dal-Pizzol F, Klamt F, Frota ML Jr et al (2001) Neonatal iron exposure induces oxidative stress in adult Wistar rat. Brain Res Dev Brain Res 130(1):109-114
44. Connor JR, Pavlick G, Karli D et al (1995) A histochemical study of iron-positive cells in the developing rat brain. J Comp Neurol 355:111-123
45. Taylor EM, Morgan EH (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res Dev Brain Res 55:35-42
46. Dwork AJ, Lawler G, Zybert PA et al (1990) An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res 518:31-39
47. Fredriksson A, Schroder N, Eriksson P et al (1999) Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol Appl Pharmacol 159(1):25-30
48. Youdim MB, Fridkin M, Zheng H (2005) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126(2):317-326
49. Riederer P, Sofic E, Rausch WD et al (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520
50. Roskams AJ, Connor JR (1994) Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem 63:709-716
51. Polla AS, Polla LL, Polla BS (2003) Iron as the malignant spirit in successful ageing. Ageing Res Rev 2: 25-37
52. Gerlach M, Foley P, Riederer P (2003) The relevance of preclinical studies for the treatment of Parkinson's disease. J Neurol 250(Suppl): I/31-I/34
53. Henchcliffe C, Schumacher HC, Burgut FT (2005) Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 5(6):811-821
54. Pallhagen S, Heinonen E, Hägglund J et al (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66(8):1200-1206
55. Ebadi M, Sharma S, Shavali S et al (2002) Neuroprotective actions of selegiline.J. Neurosci Res 67(3):285-9
56. Cohen G, Pasik P, Cohen B et al (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106:209-210
57. Matsubara K, Senda T, Uezono T et al (2001) L-deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP+, and β-carbolinium: a microdialysis study in rats. Neurosci Lett 302:65-68
58. Spooren WP, Waldmeier P, Gentsch C (1999) The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and damphetamine. J Neural Transm 106:825-833
59. Carrillo MC, Kanai S, Nokubo M et al (1992) (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 116(3):286-294
60. Kitani K, Minami C, Isobe K et al (2002) Why (-)deprenyl prolongs survivals of experimental animals: increase of antioxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev 123(8):1087-1100
61. Youdim MB, Fridkin M, Zheng H. (2005) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126(2):317-26
62. Long DA, Ghosh K, Moore AN et al (1996) Deferoxamine improves spatial memory performance following experimental brain injury in rats. Brain Res 717(1-2):109-17